151 related articles for article (PubMed ID: 32021191)
1. Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine.
Zhang X; Zhang Y; Wang Y; Wu J; Chen H; Zhao M; Peng S
Int J Nanomedicine; 2020; 15():465-481. PubMed ID: 32021191
[TBL] [Abstract][Full Text] [Related]
2. Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors.
Chen H; Lu A; Zhang X; Gui L; Wang Y; Wu J; Feng H; Peng S; Zhao M
Drug Des Devel Ther; 2018; 12():2097-2110. PubMed ID: 30022809
[TBL] [Abstract][Full Text] [Related]
3. Nano-scaled MTCA-KKV: for targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo.
Zhao S; Li Z; Huang F; Wu J; Gui L; Zhang X; Wang Y; Wang X; Peng S; Zhao M
Int J Nanomedicine; 2019; 14():4817-4831. PubMed ID: 31308660
[TBL] [Abstract][Full Text] [Related]
4. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action.
Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S
Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714
[TBL] [Abstract][Full Text] [Related]
5.
Wu J; Zhao M; Wang Y; Wang Y; Zhu H; Zhao S; Gui L; Zhang X; Peng S
Drug Des Devel Ther; 2017; 11():225-239. PubMed ID: 28176928
[TBL] [Abstract][Full Text] [Related]
6. Heptapeptide-based modification leading to enhancing the action of MTCA on activated platelets, P-selectin, GPIIb/IIIa.
Li Z; Huang F; Wu J; Gui L; Zhang X; Wang Y; Zhao S; Wang X; Peng S; Zhao M
Future Med Chem; 2018 Aug; 10(16):1957-1970. PubMed ID: 29973078
[TBL] [Abstract][Full Text] [Related]
7. Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis.
Li S; Wang Y; Wang F; Wang Y; Zhang X; Zhao M; Feng Q; Wu J; Zhao S; Wu W; Peng S
Int J Nanomedicine; 2015; 10():5273-92. PubMed ID: 26345234
[TBL] [Abstract][Full Text] [Related]
8. ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo.
Xu X; Wang Y; Wu J; Hu X; Zhu H; Zhang X; Wang Y; Gui L; Zhao M; Peng S
Int J Nanomedicine; 2017; 12():4415-4431. PubMed ID: 28652742
[TBL] [Abstract][Full Text] [Related]
9. BCESA: a nano-scaled intercalator capable of targeting tumor tissue and releasing anti-tumoral β-carboline-3-carboxylic acid.
Wu J; Cui Y; Zhang X; Gui L; Wang Y; Peng S; Zhao M
Int J Nanomedicine; 2019; 14():3027-3041. PubMed ID: 31118620
[No Abstract] [Full Text] [Related]
10. RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine.
Liu W; Mao Y; Zhang X; Wang Y; Wu J; Zhao S; Peng S; Zhao M
Int J Nanomedicine; 2019; 14():7263-7279. PubMed ID: 31686807
[TBL] [Abstract][Full Text] [Related]
11. Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α
Kuo YJ; Chang YT; Chung CH; Chuang WJ; Huang TF
Toxins (Basel); 2020 Jun; 12(7):. PubMed ID: 32605221
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models.
Feng Q; Wang M; Muhtar E; Wang Y; Zhu H
Int J Nanomedicine; 2021; 16():5777-5795. PubMed ID: 34471352
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
14. A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
Zhang X; Yang Y; Zhao M; Liu L; Zheng M; Wang Y; Wu J; Peng S
Eur J Med Chem; 2011 Aug; 46(8):3410-9. PubMed ID: 21620529
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA.
Wu J; Zhu H; Yang G; He J; Wang Y; Zhao S; Zhang X; Gui L; Zhao M; Peng S
Int J Nanomedicine; 2018; 13():1139-1158. PubMed ID: 29520141
[TBL] [Abstract][Full Text] [Related]
16. Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.
Wang X; Wang Y; Wu J; Gui L; Zhang X; Zheng M; Wang Y; Zhao S; Li Z; Zhao M; Peng S
Bioorg Med Chem Lett; 2017 Dec; 27(23):5114-5118. PubMed ID: 29108753
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy.
Cui G; Shan L; Guo L; Chu IK; Li G; Quan Q; Zhao Y; Chong CM; Zhang Z; Yu P; Hoi MP; Sun Y; Wang Y; Lee SM
Sci Rep; 2015 Jun; 5():10353. PubMed ID: 26037049
[TBL] [Abstract][Full Text] [Related]
18. A class of oral N-[(1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carbonyl]- N'-(amino-acid-acyl)hydrazine: discovery, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
Yao K; Zhao M; Zhang X; Wang Y; Li L; Zheng M; Peng S
Eur J Med Chem; 2011 Aug; 46(8):3237-49. PubMed ID: 21571404
[TBL] [Abstract][Full Text] [Related]
19. Novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids: synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation.
Wu J; Zhao M; Qian K; Lee KH; Morris-Natschke S; Peng S
Eur J Med Chem; 2009 Oct; 44(10):4153-61. PubMed ID: 19535177
[TBL] [Abstract][Full Text] [Related]
20. LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb/IIIa.
Kong Y; Wang Y; Yang W; Xie Z; Li Z
J Pharmacol Sci; 2015 Apr; 127(4):462-6. PubMed ID: 25913760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
